MDACC Study No:2012-0471 ( NCT No: NCT01709292)
Title:Pharmacodynamic study of vemurafenib in the neoadjuvant setting in patients with locally advanced thyroid cancer
Principal Investigator:Maria E. Cabanillas
Treatment Agent:Vemurafenib
Study Status:Open
Study Description:The goal of this clinical research study is to learn about how vemurafenib may
affect certain biomarkers in patients with PTC. Biomarkers are in the
blood/tissue and may be related to your reaction to the study drug. The safety
of this drug will also be studied.

Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer and cancer growth. By blocking this mutation, the drug may kill the
cancer cells with the mutation and/or stop the tumor from growing.
Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase II
Treatment Agents:Vemurafenib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Genentech
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Maria E. Cabanillas
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-563-0764
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults